

Bayer Key Data, 3rd Quarter and First Nine Months of 2018

(Continuing operations – prior-year data are restated.)

Bayer Group (EUR million)	Q3 2017	Q3 2018	Change in %	9M 2017	9M 2018	Change in %
Sales	8,025	9,905	+23.4	26,419	28,524	+8.0
EBITDA before special items	2,204	2,202	-0.1	7,505	7,433	-1.0
EBIT	1,388	4,423	+218.7	5,278	8,084	+53.2
<i>Special items</i>	-249	3,123	-	-595	2,682	-
EBIT before special items	1,637	1,300	-20.6	5,873	5,402	-8.0
Net income *	3,881	2,886	-25.6	7,188	5,639	-21.5
Earnings per share (EUR) *	4.38	2.94	-32.9	8.12	6.08	-25.1
Core earnings per share (EUR)	1.45	1.19	-17.9	5.25	4.92	-6.3
Number of employees **	99,845	118,196	+18.4	99,845	118,196	+18.4

Pharmaceuticals (EUR million)	Q3 2017	Q3 2018	Change in %	9M 2017	9M 2018	Change in %
Sales	4,065	4,163	+2.4	12,632	12,455	-1.4
EBITDA before special items	1,493	1,554	+4.1	4,476	4,332	-3.2
EBIT	1,209	1,299	+7.4	3,530	3,515	-0.4
<i>Special items</i>	3	-16	-	-153	-73	-
EBIT before special items	1,206	1,315	+9.0	3,683	3,588	-2.6

Consumer Health (EUR million)	Q3 2017	Q3 2018	Change in %	9M 2017	9M 2018	Change in %
Sales	1,320	1,297	-1.7	4,463	4,119	-7.7
EBITDA before special items	274	248	-9.5	980	817	-16.6
EBIT	155	162	+4.5	628	530	-15.6
<i>Special items</i>	-18	9	-	-42	5	-
EBIT before special items	173	153	-11.6	670	525	-21.6

Crop Science (EUR million)	Q3 2017	Q3 2018	Change in %	9M 2017	9M 2018	Change in %
Sales	2,031	3,733	+83.8	7,314	9,605	+31.3
EBITDA before special items	307	386	+25.7	1,739	2,059	+18.4
EBIT	84	3,054	-	1,171	4,100	-
<i>Special items</i>	-121	3,163	-	-253	2,822	-
EBIT before special items	205	-109	-	1,424	1,278	-10.3

Animal Health (EUR million)	Q3 2017	Q3 2018	Change in %	9M 2017	9M 2018	Change in %
Sales	359	304	-15.3	1,249	1,171	-6.2
EBITDA before special items	81	44	-45.7	332	311	-6.3
EBIT	64	31	-51.6	297	276	-7.1
<i>Special items</i>	-8	-3	-	-8	-6	-
EBIT before special items	72	34	-52.8	305	282	-7.5

EBIT(DA) before special items and core earnings per share are not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. For the definition of these indicators, see the current annual report at www.bayer.com.

* Including discontinued operations

** Full-time equivalents at end of period